Synapse - Works

Results (5599)

Dynamics of leukocyte subpopulations reconstitution predict infection propensity in a multiethnic real world cohort treated with anti-CD19 CAR-T cell therapy (axicabtagene-ciloleucel)

Meeting Abstract

Thakkar, A.; Cui, Z.; Peeke, S. Z.; Shah, N.; Lombardo, A.; Khatun, F.; Mustafa, J.; De Castro, A.; Gillick, K.; Joseph, F.; more...
Blood (2020)

Fulltext@MSK | Save

Cranial radiation can be eliminated in most children with T-cell acute lymphoblastic leukemia (T-ALL) and bortezomib potentially improves survival in children with T-cell lymphoblastic lymphoma (T-LL): Results of Children's Oncology Group (COG) trial AALL1231

Meeting Abstract

Teachey, D. T.; Devidas, M.; Wood, B. L.; Chen, Z.; Hayashi, R. J.; Annett, R. D.; Asselin, B. L.; August, K. J.; Cho, S. Y.; Dunsmore, K. P.; more...
Blood (2020)

Fulltext@MSK | Save

VRd versus KRd safety profiles in newly diagnosed multiple myeloma patients using real-world evidence data from a single institution: VRd has high rates of chronic neuropathy, and KRd has low rates of cardiopulmonary or renal toxicities when using optimized IV fluid management coupled with baseline cardiac workup

Meeting Abstract

Tan, C.; Diamond, B.; Hultcrantz, M.; Korde, N.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Patel, D.; more...
Blood (2020)

Fulltext@MSK | Save

A phase 1 study of LY3410738, a first-in-class covalent inhibitor of mutant IDH in advanced myeloid malignancies (trial in progress)

Meeting Abstract

Stein, E. M.; Konopleva, M.; Gilmour, R.; Szpurka, A. M.; Hill, E.; Ward, R.; Kantarjian, H. M.; Dinardo, C. D.
Blood (2020)

Fulltext@MSK | Save

Brentuximab vedotin with chemotherapy for patients with previously untreated, stage III/IV classical hodgkin lymphoma: 5-year update of the ECHELON-1 study

Meeting Abstract

Straus, D. J.; Dlugosz-Danecka, M.; Connors, J. M.; Illés, A.; Picardi, M.; Lech-Marańda, E.; Feldman, T.; Smolewski, P.; Savage, K. J.; Bartlett, N. L.; more...
Blood (2020)

Fulltext@MSK | Save

The tumor associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B-cell lymphoma

Meeting Abstract

Takata, K.; Chong, L. C.; Ennishi, D.; Thakur, A.; Healy, S.; Viganò, E.; Dao, T.; Nielsen, J. S.; Ben-Neriah, S.; Aoki, T.; more...
Blood (2020)

Fulltext@MSK | Save

Initial results from a biomarker-directed phase 2 trial of SY-1425, a potent and selective RAR alpha agonist, in combination with azacitidine in relapsed/refractory acute myeloid leukemia

Meeting Abstract

Stein, E. M.; De Botton, S.; Cluzeau, T.; Pigneux, A.; Liesveld, J. L.; Cook, R. J.; Rousselot, P.; Rizzieri, D. A.; Braun, T.; Bixby, D. L.; more...
Blood (2020)

Fulltext@MSK | Save

Enasidenib (ENA) monotherapy with addition of azacitidine in non-responders is effective in older patients with newly diagnosed IDH2 mutated acute myeloid leukemia (AML): A completed phase 2/1b sub-study of the beat AML master trial

Meeting Abstract

Stein, E. M.; Huang, Y.; Borate, U.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Schiller, G. J.; Olin, R. L.; Foran, J. M.; more...
Blood (2020)

Fulltext@MSK | Save

Venetoclax therapy for relapsed and treatment refractory AML: Clinical outcomes and molecular predictors

Meeting Abstract

Stahl, M.; Menghrajani, K.; Derkach, A.; Chan, A.; Xiao, W.; Glass, J. L.; King, A. C.; Daniyan, A.; Famulare, C.; Cuello, B. M.; more...
Blood (2020)

Fulltext@MSK | Save

Clinical outcomes of acute myeloid leukemia patients bridged to allogeneic stem cell transplant by venetoclax combination therapy

Meeting Abstract

Stahl, M.; Menghrajani, K.; Derkach, A.; DeWolf, S.; Ruiz, J. D.; Ponce, D. M.; Shaffer, B. C.; Tamari, R.; Young, J. W.; Barker, J.; more...
Blood (2020)

Fulltext@MSK | Save